Výsledky vyhledávání - Andreas Viardot

Upřesnit hledání
  1. 1
    Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

    Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies Autor Andreas Viardot, Franco Locatelli, Julia Stieglmaier, Faraz Zaman, Elias Jabbour

    Vydáno 2020
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Prostaglandin E2 Inhibits IFN-α Secretion and Th1 Costimulation by Human Plasmacytoid Dendritic Cells via E-Prostanoid 2 and E-Prostanoid 4 Receptor Engagement

    Prostaglandin E2 Inhibits IFN-α Secretion and Th1 Costimulation by Human Plasmacytoid Dendritic Cells via E-Prostanoid 2 and E-Prostanoid 4 Receptor Engagement Autor Dorit Fabricius, Marina Neubauer, Birgit Mandel, Catharina Schütz, Andreas Viardot, Angelika Vollmer, Bernd Jahrsdörfer, Klaus‐Michael Debatin

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma

    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma Autor Myron S. Czuczman, Georg Heß, Ole Gadeberg, Lars Møller Pedersen, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Claus Strange, Kristian Windfeld, Andreas Viardot

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

    Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia Autor Gerhard Zugmaier, Max S. Topp, Shilpa Alekar, Andreas Viardot, H-A Horst, Svenja Neumann, Matthias Stelljes, R C Bargou, Mariele Goebeler, Dorothea Wessiepe, Evelyn Degenhard, Nicola Gökbuget, Matthias Klinger

    Vydáno 2014
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

    Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma Autor Andreas Viardot, Marie-Elisabeth Goebeler, Georg Heß, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, M. Libicher, Cyrus Sayehli, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL Autor Niels Murawski, Michael Pfreundschuh, Samira Zeynalova, Viola Poeschel, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Christian Schmidt, Michael Hallek, Mathias Witzens‐Harig, Lorenz Trümper, Torben Rixecker, C. Zwick

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    CD5<sup>+</sup> B cells from individuals with systemic lupus erythematosus express granzyme B

    CD5<sup>+</sup> B cells from individuals with systemic lupus erythematosus express granzyme B Autor Magdalena Hagn, Verena Ebel, Kai Sontheimer, Elisabeth Schwesinger, Oleg Lunov, Thamara Beyer, Dorit Fabricius, Thomas F.E. Barth, Andreas Viardot, Stephan Stilgenbauer, Julia Hepp, Karin Scharffetter‐­Kochanek, Thomas Simmet, Bernd Jahrsdörfer

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement

    Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement Autor Gerhard Held, Samira Zeynalova, Niels Murawski, Marita Ziepert, B. Kempf, Andreas Viardot, Martin Dreyling, Michael Hallek, Mathias Witzens‐Harig, Jochen Fleckenstein, Christian Rübe, Carsten Zwick, Bertram Glaß, Norbert Schmitz, Michael Pfreundschuh

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    <sup>90</sup>Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial

    <sup>90</sup>Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial Autor Christian W. Scholz, Antonio Pinto, Werner Linkesch, Ola Lindén, Andreas Viardot, Ulrich Keller, Georg Heß, Secondo Lastoria, Kristina Lerch, Ferdinando Frigeri, Manuela Arcamone, Andrea Stroux, Bernd Frericks, Christiane Pott, Antonio Pezzutto

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

    Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia Autor Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, Peter Kufer, Matthias Stelljes, Andreas Viardot, Heinz A. Horst, Svenja Neumann, Monika Brüggemann, Oliver G. Ottmann, Thomas Burmeister, Dorothea Wessiepe, Max S. Topp, Ralf C. Bargou

    Vydáno 2017
    Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

    Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Res... Autor Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuß, Bernd Hertenstein, Anne C. Wilke, Simon Raffel, Nadja Jäkel, Vladan Vučinić, Dirk Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

    Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment Autor Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz-A. Horst, Reinhard Marks, Christoph Faul, H. Diedrich, Albrecht Reichle, Monika Brüggemann, Chris Holland, Margit Schmidt, Hermann Einsele, Ralf C. Bargou, Max S. Topp

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

    Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgk... Autor Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Martin Dreyling, Michael Hallek, Carsten Mueller, Martin H. J. Wiesen, Mathias Witzens‐Harig, Lorenz Truemper, Ulrich Keller, Tanja Rixecker, Carsten Zwick, Niels Murawski

    Vydáno 2014
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

    Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab Autor Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation

    High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation Autor Nicola Gökbuget, Nadežda Basara, H. Baurmann, Joachim Beck, Monika Brüggemann, H. Diedrich, B. Güldenzoph, G. Hartung, Heinz‐August Horst, Andreas Hüttmann, Guido Kobbe, Ralph Naumann, Richard Ratei, Albrecht Reichle, Hubert Serve, Matthias Stelljes, Andreas Viardot, Mohammed Wattad, Dieter Hoelzer

    Vydáno 2011
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Potential clinical implications of<i>BRAF</i>mutations in histiocytic proliferations

    Potential clinical implications of<i>BRAF</i>mutations in histiocytic proliferations Autor Anna-Maria Bubolz, Stephanie E. Weissinger, Albrecht Stenzinger, Annette Arndt, Konrad Steinestel, Silke Brüderlein, Holger Cario, Anneli Lubatschofski, Claudia Welke, Ioannis Anagnostopoulos, Thomas F.E. Barth, Ambros J. Beer, Peter M√oller, M. H. Gottstein, Andreas Viardot, Jochen K. Lennerz

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

    Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphobl... Autor Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Petra Klappers, Matthias Stelljes, Svenja Neumann, Andreas Viardot, Reinhard Marks, H. Diedrich, Christoph Faul, Albrecht Reichle, Heinz‐August Horst, Monika Brüggemann, Dorothea Wessiepe, Chris Holland, Shilpa Alekar, Noemi Mergen, Hermann Einsele, Dieter Hoelzer, Ralf C. Bargou

    Vydáno 2014
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

    Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation Autor Nicola Gökbuget, Daniel Stanze, Joachim Beck, H. Diedrich, Heinz‐August Horst, Andreas Hüttmann, Guido Kobbe, Karl‐Anton Kreuzer, Lothar Leimer, Albrecht Reichle, Markus Schaich, Stefan Schwartz, Hubert Serve, Michael Starck, Matthias Stelljes, Reingard Stuhlmann, Andreas Viardot, Knut Wendelin, Mathias Freund, Dieter Hoelzer

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20<sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

    Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20<sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborati... Autor Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nöel Milpied, John Radford, Nicolas Ketterer, Ofer Shpilberg, Ulrich Dührsen, Hans Hagberg, Daniel David, Andreas Viardot, Ray M. Lowenthal, Josette Brière, Gilles Salles, Craig H. Moskowitz, Bertram Glaß

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

    Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study Autor Gilles Salles, Stephen J. Schuster, Sven de Vos, Nina D. Wagner‐Johnston, Andreas Viardot, Kristie A. Blum, Christopher R. Flowers, Wojciech Jurczak, Ian W. Flinn, Brad S. Kahl, Peter Martin, Yeonhee Kim, Sanatan Shreay, Matthias Will, Bess Sorensen, Madlaina Breuleux, Pier Luigi Zinzani, Ajay K. Gopal

    Vydáno 2016
    Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: